Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PerioPatch is a muco-adhesive oral patch developed by Izun Pharmaceuticals for the localized treatment of inflammatory conditions in the mouth, including gingivitis, periodontitis, and oral lesions. The patch functions by adhering to the gingival tissue, providing a physical barrier that protects the affected area from further irritation while delivering a concentrated dose of botanical extracts. These extracts, typically derived from *Centella asiatica*, *Echinacea purpurea*, and *Sambucus nigra*, possess anti-inflammatory and wound-healing properties that help reduce swelling, pain, and bleeding. By maintaining contact with the site of inflammation for several hours, PerioPatch facilitates the natural healing process of the oral mucosa and is often used as an adjunct to professional dental procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PerioPatch.